Kura Oncology is trading 5.25% down at $11.46 amid broad market weakness following hotter-than-expected producer inflation and renewed concerns about delayed Federal Reserve easing.
- The S&P 500, Nasdaq Composite, and Dow Jones Industrial Average are each down more than 0.5%.
- Kura’s Caspian Therapeutics spinout, backed by $50 million including Eli Lilly, was reported September 9; available coverage does not directly link it to the decline.